| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
17.30
|
|
2
|
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
|
J Clin Oncol
|
2004
|
12.89
|
|
3
|
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
|
Lancet
|
2005
|
12.30
|
|
4
|
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
|
Lancet
|
2009
|
8.73
|
|
5
|
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
|
J Clin Oncol
|
2009
|
7.80
|
|
6
|
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
|
J Clin Oncol
|
2003
|
5.84
|
|
7
|
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
|
Lancet Oncol
|
2011
|
5.06
|
|
8
|
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
4.58
|
|
9
|
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2006
|
3.52
|
|
10
|
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
|
Lancet Oncol
|
2011
|
3.24
|
|
11
|
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
3.13
|
|
12
|
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
2.92
|
|
13
|
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
2.69
|
|
14
|
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
|
Oncologist
|
2005
|
2.17
|
|
15
|
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
|
Lancet Oncol
|
2010
|
2.05
|
|
16
|
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.80
|
|
17
|
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.77
|
|
18
|
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
|
Lung Cancer
|
2006
|
1.75
|
|
19
|
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.67
|
|
20
|
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
|
J Clin Oncol
|
2009
|
1.64
|
|
21
|
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
|
J Clin Oncol
|
2012
|
1.55
|
|
22
|
The emerging role of MET/HGF inhibitors in oncology.
|
Cancer Treat Rev
|
2013
|
1.54
|
|
23
|
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
|
J Clin Oncol
|
2012
|
1.52
|
|
24
|
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
|
J Natl Cancer Inst
|
2003
|
1.49
|
|
25
|
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
|
Clin Lung Cancer
|
2012
|
1.40
|
|
26
|
Clinical relevance of circulating nucleosomes in cancer.
|
Ann N Y Acad Sci
|
2008
|
1.23
|
|
27
|
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
|
Clin Cancer Res
|
2008
|
1.22
|
|
28
|
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.14
|
|
29
|
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
|
Lung Cancer
|
2009
|
1.11
|
|
30
|
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
1.08
|
|
31
|
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
|
Lung Cancer
|
2008
|
1.03
|
|
32
|
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
|
J Clin Oncol
|
2008
|
1.02
|
|
33
|
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
|
J Thorac Oncol
|
2010
|
0.98
|
|
34
|
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
|
Invest New Drugs
|
2012
|
0.96
|
|
35
|
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2007
|
0.94
|
|
36
|
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.94
|
|
37
|
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.92
|
|
38
|
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.90
|
|
39
|
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
|
Oncol Rep
|
2012
|
0.88
|
|
40
|
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
|
J Thorac Oncol
|
2008
|
0.86
|
|
41
|
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.85
|
|
42
|
Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
|
Clin Chem Lab Med
|
2003
|
0.83
|
|
43
|
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
|
Lung Cancer
|
2012
|
0.82
|
|
44
|
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
|
Oncology
|
2012
|
0.81
|
|
45
|
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
|
Lung Cancer
|
2013
|
0.80
|
|
46
|
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
|
Lung Cancer
|
2006
|
0.80
|
|
47
|
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.79
|
|
48
|
Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.
|
Curr Med Res Opin
|
2007
|
0.77
|
|
49
|
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.
|
Lung Cancer
|
2003
|
0.75
|
|
50
|
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
|
Lung Cancer
|
2013
|
0.75
|
|
51
|
Editorial.
|
Int J Clin Pharmacol Ther
|
2015
|
0.75
|
|
52
|
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
|
Oncol Res Treat
|
2017
|
0.75
|
|
53
|
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
|
Respir Med
|
2009
|
0.75
|
|
54
|
Annual meeting of CESAR in Tuebingen, Germany June 27-29, 2013.
|
Int J Clin Pharmacol Ther
|
2014
|
0.75
|
|
55
|
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].
|
Onkologie
|
2006
|
0.75
|